Document Detail

Blood microbiota dysbiosis is associated with the onset of cardiovascular events in a large general population: the d.e.s.I.R. Study.
Jump to Full Text
MedLine Citation:
PMID:  23372728     Owner:  NLM     Status:  In-Data-Review    
AIM: We recently described a human blood microbiome and a connection between this microbiome and the onset of diabetes. The aim of the current study was to assess the association between blood microbiota and incident cardiovascular disease.
METHODS AND RESULTS: D.E.S.I.R. is a longitudinal study with the primary aim of describing the natural history of the metabolic syndrome and its complications. Participants were evaluated at inclusion and at 3-, 6-, and 9-yearly follow-up visits. The 16S ribosomal DNA bacterial gene sequence, that is common to the vast majority of bacteria (Eubac) and a sequence that mostly represents Proteobacteria (Pbac), were measured in blood collected at baseline from 3936 participants. 73 incident cases of acute cardiovascular events, including 30 myocardial infarctions were recorded. Eubac was positively correlated with Pbac (r = 0.59; P<0.0001). In those destined to have cardiovascular complications, Eubac was lower (0.14±0.26 vs 0.12±0.29 ng/µl; P = 0.02) whereas a non significant increase in Pbac was observed. In multivariate Cox analysis, Eubac was inversely correlated with the onset of cardiovascular complications, (hazards ratio 0.50 95% CI 0.35-0.70) whereas Pbac (1.56, 95%CI 1.12-2.15) was directly correlated.
CONCLUSION: Pbac and Eubac were shown to be independent markers of the risk of cardiovascular disease. This finding is evidence for the new concept of the role played by blood microbiota dysbiosis on atherothrombotic disease. This concept may help to elucidate the relation between bacteria and cardiovascular disease.
Jacques Amar; Céline Lange; Gaëlle Payros; Celine Garret; Chantal Chabo; Olivier Lantieri; Michael Courtney; Michel Marre; Marie Aline Charles; Beverley Balkau; Rémy Burcelin;
Related Documents :
1018478 - Changes in anticoagulation in dogs assayed by three methods.
8545578 - Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage.
4011898 - The calcar avis: demonstration with cranial us.
8353348 - Acute clot-trapping efficiency in dogs with compacted versus elongated wires in bird's ...
16914478 - A novel hydrodynamic approach to the treatment of coronary artery disease.
1381778 - Cerebral vasodilating and spasmolytic actions of a new ca-antagonist, clentiazem (ta-30...
Publication Detail:
Type:  Journal Article     Date:  2013-01-25
Journal Detail:
Title:  PloS one     Volume:  8     ISSN:  1932-6203     ISO Abbreviation:  PLoS ONE     Publication Date:  2013  
Date Detail:
Created Date:  2013-02-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101285081     Medline TA:  PLoS One     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e54461     Citation Subset:  IM    
INSERM U1048, Institute of Research on Metabolic and Cardiovascular Diseases, CHU Toulouse, Toulouse, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
ISSN: 1932-6203
Publisher: Public Library of Science, San Francisco, USA
Article Information
Download PDF
Copyright: 2013 Amar et al
Received Day: 7 Month: 10 Year: 2012
Accepted Day: 11 Month: 12 Year: 2012
collection publication date: Year: 2013
Electronic publication date: Day: 25 Month: 1 Year: 2013
Volume: 8 Issue: 1
E-location ID: e54461
PubMed Id: 23372728
ID: 3555817
Publisher Id: PONE-D-12-30802
DOI: 10.1371/journal.pone.0054461

Blood Microbiota Dysbiosis Is Associated with the Onset of Cardiovascular Events in a Large General Population: The D.E.S.I.R. Study Alternate Title:Blood Microbiota Dysbiosis and Cardiac Events
Jacques Amar1*
Céline Lange23
Gaëlle Payros4
Celine Garret4
Chantal Chabo14
Olivier Lantieri5
Michael Courtney6
Michel Marre78
Marie Aline Charles23
Beverley Balkau23
Rémy Burcelin14 On behalf of: for the D.E.S.I.R. Study Group
D.E.S.I.R. Study Group
Antony Bayeredit1 Role: Editor
1INSERM U1048, Institute of Research on Metabolic and Cardiovascular Diseases, CHU Toulouse, Toulouse, France
2INSERM, CESP Centre for research in Epidemiology and Population Health, U1018, Epidemiology of Diabetes, Obesity and Chronic Kidney Disease Over the Lifecourse, Villejuif, France
3University Paris Sud 11, UMRS 1018, Villejuif, France
4Bio-Medical Research Federative Institute of Toulouse, Toulouse, France
5IRSA, La Riche, France
6VAIOMER SAS, Toulouse, France
7Service d'endocrinologie-diabète-nutrition, Groupe Hospitalier Bichat-Claude Bernard, Assistance Publique des Hôpitaux de Paris, Paris, France
8INSERM U695, Université Denis Diderot Paris 7, Paris, France
Cardiff University, United Kingdom
Correspondence: * E-mail:
[conflict] Competing Interests: The authors received funding from commercial sources: Lilly, Novartis Pharma and Sanofi-Aventis, Ardix Medical, Bayer Diagnostics, Becton Dickinson, Cardionics, Merck Santé, Novo Nordisk, Pierre Fabre, Roche, Topcon. The authors also declare that Remy Burcelin, Chantal Chabo, Beverley Balkau and Jacques Amar are listed as coinventors on patents held by the National Institute for Health and Medical Research (INSERM) that relate to the use of bacterial DNA in metabolic diseases. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Contributed by footnote: Conceived and designed the experiments: JA RB BB. Performed the experiments: CL GP CG CC . Analyzed the data: OL MM MC MAC. Wrote the paper: JA CL RB MM BB.
[other] ¶ Membership of the D.E.S.I.R. Study Group is provided in the Acknowledgments.


Treatment of traditional cardiovascular risk factors has resulted in a dramatic decrease in the incidence of cardiovascular disease over the past 30 years [1], [2]. Despite progress, cardiovascular disease remains the leading cause of mortality throughout the world, including in developed countries. More importantly, even in well treated and controlled high-risk cardiovascular patients, an important residual cardiovascular risk persists [3], [4]. Beside the role of traditional risk factors, experimental and epidemiological evidence that infection is involved in the onset of atherosclerotic diseases continues to mount [5][11].Interestingly, the role of gram negative bacteria on arterial wall structure and function has been studied. Wiederman et al [12] showed an association between endotoxemia and carotid atherosclerosis in a prospective population-based study. In line with this data, our group reported in a population-based study, a correlation between aortic stiffness and soluble CD14 blood level, the main endotoxin receptor [13]. A randomized trial showed that a vaccination against gram negative bacteria resulted in aortic stiffening [14]. Furthermore, the presence of bacteria from intestinal or oral origin have been observed in atherosclerotic plaques and importantly, compared with oral and gut samples, atherosclerotic plaque contained significantly higher levels of Proteobacteria (Pbac) and fewer Firmicutes [15]. In this respect, we recently described a human blood microbiome [16]. As for gut microbiota, this result introduced the concept of tissue microbiota equilibrium as a potential factor in human health. Indeed, a body of evidence shows that gut microbiota dysbiosis plays a key role in various diseases such as type 1 diabetes [17], bowel diseases [18], [19] and celiac disease [20]. For example, in inflammatory bowel diseases, reduced microbial diversity was observed [18]. Fecal samples from patients with celiac disease had lower proportions of Bifidobacterium and increased proportions of Bacteroides/Prevotella[20]. In the light of these data, rather than analyse the role of few selected pathogens, we sought to explore the effect of blood microbiota equilibrium on the onset of cardiovascular diseases in a general population, with a focus on proteobacteria phylum.


D.E.S.I.R. (Data from an Epidemiological Study on the Insulin Resistance syndrome) is a longitudinal cohort study of 5,212 adults aged 30–65 years at baseline; the primary aim of the study was to describe the natural history of the metabolic syndrome [21]. Participants were recruited in 1994–1996 from ten Social Security Health Examination centers in central-western France, from volunteers insured by the French national social security system (80% of the French population - any employed or retired person and their dependents are offered free periodic health examinations). Equal numbers of men and women were recruited in five-year age groups. All participants gave written informed consent, and the study protocol was approved by the CCPPRB (Comité Consultatif de Protection des Personnes pour la Recherche Biomédicale) of the Hôpital Bicêtre (Paris, France). Participants were clinically and biologically evaluated at inclusion and at 3-, 6, and 9-yearly follow-up visits. We excluded participants without data on the Pbac gene, Eubac gene, LDL-cholesterol, smoking, diabetes, hypertension or fibrinogen, and those who were likely to have infections: fibrinogen >5 mg/l, abundant leucocyturia, taking antiviral therapy and extreme blood bacterial DNA levels.

Parameters Studied

The examining physician recorded the history of cardiovascular diseases and treatment for diabetes and hypertension. Smoking habits were documented in a self-administered questionnaire. Smokers were defined as those currently smoking ≥1 cig/day at inclusion or who quit smoking less than 3 years prior to the survey. Two measures of blood pressure were taken in a supine position after a 5 min rest; mean values were used. Participants were defined as having hypertension if they were treated for hypertension, or if their systolic/diastolic blood pressures were ≥140/90 mmHg. Weight and height were measured in lightly clad participants, and body mass index was calculated. The waist perimeter was measured horizontally at the smallest circumference between the lower rib and the iliac crests. Participants were followed until the end of the study or until a cardiovascular event occurred.

Primary outcome

The primary outcome was the first occurrence of a myocardial infarction (fatal or not), a diagnosis of myocardial ischemia and/or significant coronary stenosis determined either by coronary angiogram or scintigraphy, revascularization therapy or a cerebral infarction. These events were physician adjudicated by medical record review with information provided by treating physicians and hospitals, in participants who, on the follow-up questionnaires, reported new cardiovascular disease, chest pain, stroke, or leg pain when walking.

Biological Analyses

Blood was drawn after a 12-h fast. All biochemical measurements except bacterial DNA analysis were from one of four health center laboratories located in France at Blois, Chartres, La Riche, or Orléans. Fasting plasma glucose measured by the glucose oxidase method, was applied to fluoro-oxalated plasma using a Technicon RA100 (Bayer Diagnostics, Puteaux, France) or a Specific or a Delta device (Konelab, Evry, France). Total-cholesterol, HDL-cholesterol and triglycerides were measured by enzymatic methods; LDL-cholesterol was calculated from the Friedewald equation; fibrinogen was quantified by nephelometry and leucocytes by flow cytometry. Aspartate amino transferase (AST) and Alanine aminotransferase (ALT) activities were measured at 37°C with an automatic analyser (Technicon Dax 24; Bayer Diagnostics; or Lab 20 or Delta 60i; Konelab).

Proteobacteria phylum quantification within blood microbiota

The 16S ribosomal DNA bacterial gene sequences were measured in blood collected at baseline. We studied the 16S rDNA gene as some regions of this gene are highly conserved between different species of bacteria and it is considered a marker of the overall microbiota [22]. In addition to highly conserved primer binding sites, the 16S rRNA gene sequences contain hypervariable regions that can provide species-specific signature sequences useful for bacterial identification. The 16S ribosomal DNA gene sequence common to the vast majority of the bacteria phyla (Eubac) and the 16S rDNA sequences that belong to the Proteobacteria phylum (Pbac) were measured in blood at baseline. The 16SrDNA qPCR technique has been established as follows. Using both sets of primers (Eubac and Pbac) the efficacy of PCR amplification has been calculated against a pure E. coliBl21 DNA standard curve from 0.001 to 10 ng/µl and found linear (∼95% efficacy). The rate of amplification was found close to 100%. It was calculated as well according to the following formula A = b.2n where A is the expected amount of amplified DNA, b is the amount of DNA to be amplified, and n is the number of PCR cycles Similarly, the efficacy of PCR amplification for each sample has been established and found similar to that obtained for the standard curve. However, due to the large diversity of bacterial DNA in each sample, the rate of amplification could not be calculated precisely. This rate is expected to be better for Pbac PCR than for Eubac, based on the dominance of the Proteobacteriacae family [16]. Therefore, the ratios obtained between Pbac and Eubac are expected to be higher than 1.

Bacterial DNA preparation

DNA was extracted from peripheral blood leukocytes using a classical phenol/chloroform extraction method followed by alcohol precipitation (ice-cold 70% alcohol). Air dried DNA was re-suspended in Tris EDTA and stored at −80°C before use [23], [24]. This method did not use glass microbeads to increase the efficiency of bacterial DNA extraction, which is commonly employed in current methods, as at the time of sample preparation, the isolation of bacterial DNA was not the goal of the work. However, despite this important technical difference, we succeeded in amplifying 16S rDNA from blood. To validate the difference between these two extraction procedures, we extracted total blood DNA in the presence and in the absence of microbeads. The efficacy of bacterial DNA extraction, as assessed by 16S rDNA qPCR amplification, was 10 times higher using microbead, although the absolute value of the bacterial DNA concentration was higher, the proportions between samples remained the same.

Eubacteria quantitation

Total DNA concentration was determined using the Quant-iTTM dsDNA Broad-Range Assay Kit (Invitrogen). The mean concentration was 121.1±208.3 ng/µl. Each sample was diluted ten-fold in Tris buffer EDTA. The DNA was amplified by realtime PCR (Stepone+; Applied Biosystems) in optical grade 96-well plates. The PCR reaction was performed in a total volume of 25 µl using the Power SYBR® Green PCR master mix (Applied Biosystems), containing 300 nM of each of the universal forward and reverse primers eubac-F ([gene: 5′-TCCTACGGGAGGCAGCAGT-3′]) and eubac-R ([gene: 5′-GGACTACCAGGGTATCTAATCCTGTT-3′]). The reaction conditions for amplification of DNA were 95°C for 10 min and 35 cycles of 95°C for 15 s and 60°C for 1 min. The amplification step was followed by a melting curve step according to the manufacturer's instructions (from 60°C to 90°C) to determine the specificity of the amplification product obtained. The amount of amplified DNA was determined using a standard curve obtained by real time PCR from dilutions ranging from 0.001 to 10 ng/µl of E. coli BL21 total DNA.

Proteobacteria quantitation

The DNA coding the 16S rDNA was amplified as described above using forward and reverse primers Proteobac-F (F-Bact1369) ([gene: 5′- CGGTGAATACGTTCCCGG-3′]) and Proteobac -R (R-Prok1492) ([gene: 5′- TACGGCTACCTTGTTACGACTT -3′]) as described by Valladares et al [25]. These primers amplify a subset of 16SrDNA which corresponds mostly to Proteobacteria as determine by Blast analysis of the forward primer against the RDP database. The reaction conditions for amplification of DNA were 50°C for 2 min, 95°C for 10 min and 40 cycles of 95°C for 15 s, 60°C for 1 min and 72°C for 30 s. The amplification step was followed by a melting curve step according to the manufacturer's instructions (from 60°C to 95°C) to determine the specificity of the amplification product obtained. The amount of amplified DNA was determined using a standard curve obtained by real time PCR from dilutions ranging from 0.001 to 10 ng/µl of E. coli BL21 total DNA.

Statistical analyses

SAS version 9.2 was used for statistical analysis. For analyses, the bacterial gene concentrations were log transformed, as the distributions were skewed; triglyceride concentrations were also log-transformed.

Baseline characteristics of participants are shown as mean ± SD, geometric */÷ eSD (where SD is the standard deviation of the log-transformed variable) or as n (%), and they were compared between those destined to have acute cardiovascular events and those who were not, using t-tests or χ2 tests. Baseline characteristics of participants were compared over tertiles of Eubac and Pbac, by regression analysis for continuous variables and by the Armitage trend test for percentages. Standardised hazards ratios associated with cardiovascular events were calculated from Cox models, with age as the time variable, and after adjustment for sex, baseline hypertension, diabetes, smoking status, LDL-cholesterol, and fibrinogen. The proportional hazards assumption of the Cox model was checked by including an interaction term between the time variable and bacterial gene concentrations as continuous variables. The linearity of the relations with Eubac and Pbac were checked by the addition of a squared term to the models.

Characteristics of the studied population

At baseline, among the 5212 participants in the D.E.S.I.R. study, 183 presented biological signs of infection or received antiviral therapy. The whole battery of major cardiovascular risk factors was not available in 77 volunteers, 490 did not undergo proteobacteria gene or Eubac gene determination and 526 were lost to follow-up. These volunteers were excluded from the analysis. They were significantly younger and less frequently smokers as compared with analyzed subjects. The characteristics of the study population (n = 3936) are shown in Table 1, and traditional risk factors were higher in those with incident cardiovascular events as compared with controls.

Pbac was positively correlated with Eubac (r = 0.59; P<0.0001) (Figure 1). Similar relations were observed for Pbac and Eubac and major cardiovascular risk factors. Age, blood pressures, fibrinogen and ALT increased over tertiles of Pbac and Eubac, whereas the percentage of current smokers decreased (Tables 2, 3). No significant relation was reported with other traditional risk factors such as LDL-cholesterol or fasting blood glucose.

Prediction of acute cardiovascular events and microbiota

We recorded 73 incident cases of acute cardiovascular events, including 30 myocardial infarctions (2 fatal), 26 with revascularization therapy, 11 significant myocardial ischemia diagnosed either by coronarography or scintigraphy and 6 cranial infarctions during an average follow-up time of 101±22 months. Eubac was significantly lower in patients destined to have cardiovascular events. A non significant increase in Pbac concentration was also observed (Table 1). In multivariate Cox model analysis, after adjustment for confounders, Eubac was negatively correlated with primary outcome. When Pbac was added to the model, Eubac remained negatively correlated with the onset of primary outcome and Pbac was positively linked (Table 4). We present the hazard ratio for primary outcome by tertiles of Eubac and Pbac (Figure 2). A 3.7 fold increase in the risk of cardiovascular events was observed between volunteers who had the lowest levels of Eubac and the highest level of Pbac as compared with those who had the highest levels of Eubac and the lowest level of Pbac (P for trend 0.003).


The main finding of the study is that a dysbiosis in blood microbiota, defined by a decrease in blood bacterial DNA content and an increase in the proportion of Proteobacteria phylum within blood microbiota, predicts long-term cardiovascular prognosis. Since this study is the first to raise this concept, confirmatory study is required.

Until now, most of the epidemiological evidence that supports a relation between infection and cardiovascular events is based on associations between circulating antibacterial antibodies and cardiovascular diseases [7], [10]. For example, it has been shown that antibodies against oral pathogens were correlated either with target organ damage [26] or with the onset of cardiovascular events [27]. Based on this indirect approach, various pathogens were identified as predictors of cardiovascular diseases. Also, the presence of pathogens within plaque has been previously established [28], in coronary lesions as well: using human specimens obtained during coronary atherectomy, the “fingerprints” of more than 50 different bacterial species have been observed [29]. Therefore, it seems unlikely that a single pathogen is a key for the onset of cardiovascular events [30]. In addition to these results, our findings show that beyond the diversity of pathogens associated with cardiovascular diseases, tissue microbiota equilibrium could be involved in the mechanism underlying the relation between infection and atherosclerotic events.

The concept of microbiota dysbiosis as a key player in the course of various diseases has been proposed for gut [31][33] and oral microbiota [34], [35]. Changes in gut microbiota equilibria operate on pathological processes, either systematically through inflammatory mediators or locally. For example obesity has been associated with inflammation gut-mediated microbiota dysbiosis [36] whereas in inflammatory bowel disease, gut microbiota dysbiosis impacts on bile acid modification, which in turn has a direct deleterious effect on the disease [37]. To the best of our knowledge, our results are the first to show that microbiota dysbiosis is a player in pathological processes in cardiovascular disease.

This new paradigm may help to elucidate the relation between bacteria and cardiovascular disease. Indeed, whereas the aforementioned evidence supports the role of various pathogens, most interventional trials aiming to test antibiotics targeting these pathogens in the treatment of atherosclerosis, failed to improve cardiovascular prognostic [38]. In this respect, the resilience of the microbial community to a short-course antibiotic challenge has been repeatedly established [39], [40]. For example, in healthy volunteers the fecal microbiota showed a major shift in dominant species on antibiotic treatment, starting 24 h after treatment initiation. Within 30 days following antibiotic treatment, the fecal microbiota had an average similarity of 88% to baseline. It is likely that this resilience exists within human tissue and may contribute to explain the failure of antibiotic therapy administered over a short period of time, to prevent cardiovascular events. However, it seems possible to cause a shift to an alternative stable state. For example, the effect of repeated antibiotic perturbations have been tested in humans and it has been show that as soon as one week after the end of each course of antibiotics, gut microbiota begin to return to their initial state, but the return was often incomplete [41]. Taken together, these data may help to design some new interventional trials targeting tissue microbiota dysbiosis to prevent cardiovascular diseases.

Surprisingly, we observed a negative correlation between blood bacterial DNA as a whole or proteobacteria DNA and current smoking. In this respect, no change in lipopolysaccharide (LPS) concentration has been observed in an intervention trial [42] after cigarette smoking. Furthermore, no difference in blood LPS concentration has been found in current smokers as compared with non-smokers [43]. At this stage, no firm conclusion can be drawn from our current results. We can only hypothesize that an important change in tissue microbiota should be associated with current smoking. Importantly, we failed to find consistent relations between blood bacterial DNA and lipoprotein levels suggesting that these lipoproteins did not play a major role on blood bacterial DNA burden. Also, with respect to the body of evidence supporting a link between non-alcoholic fatty liver disease [44] and cardiovascular prognosis, we showed a positive correlation between Eubac and Pbac and ALT raising the interesting hypothesis of tissue microbiota dysbiosis as a common soil for non-alcoholic steatosis hepatitis and cardiac diseases.

In conclusion, our study demonstrates for the first time, that a microbiota dysbiosis predicts acute cardiovascular events in a large general population. This innovative concept opens new ways to predict and perhaps even prevent cardiovascular diseases.

The D.E.S.I.R. Study Group: INSERM CESP U1018: B Balkau, P Ducimetière, E Eschwège; INSERM U367: F Alhenc-Gelas; CHU d'Angers: A Girault; Bichat Hospital: F Fumeron, M Marre, R Roussel; CHU de Rennes: F Bonnet; Centre National de la Recherche Scientifique UMR 8090, Lille: S, Cauchi, P Froguel; Institute de Recherche Médecine Générale: J Cogneau; Institute inter Regional pour la Santé: C Born, E Caces, N Copin, JG Moreau, O Lantieri, F Rakotozafy, J Tichet, and S Vol.

1. Carandang R,, Seshadri S,, Beiser A,, Kelly-Hayes M,, Kase CS,, et al. (Year: 2006) Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA296: 2939–294617190894
2. Yeh RW,, Sidney S,, Chandra M,, Sorel M,, Selby JV,, et al. (Year: 2010) Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med362: 2155–216520558366
3. Blacher J,, Evans A,, Arveiler D,, Amouyel P,, Ferrières J,, et al. (Year: 2004) PRIME Study Group. Residual coronary risk in men aged 50–59 years treated for hypertension and hyperlipidaemia in the population: the PRIME study. J Hypertens22: 415–42315076202
4. Helfand M,, Buckley DI,, Freeman M,, Fu R,, Rogers K,, et al. (Year: 2009) Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med151: 496–49719805772
5. Gilbert A,, Lion G, (Year: 1889) Artérites infectieuses expérimentales. Comptes Rendus Hebdomadaires des Séances et Mémoires de la Société de Biologie41: 583–584
6. Maass M,, Bartels C,, Engel PM,, Mamat U,, Sievers HH, (Year: 1998) Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol15: 827–8329525555
7. Espinola-Klein C,, Rupprecht HJ,, Blankenberg S,, Bickel C,, Kopp H,, et al. (Year: 2002) AtheroGene Investigators. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation105: 15–2111772870
8. Madjid M,, Naghavi M,, Litovsky SA,, Casscells SW, (Year: 2003) Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies. Circulation108: 2730–614610013
9. Smeeth L,, Thomas SL,, Hall AJ,, Hubbard R,, Farrington P,, et al. (Year: 2004) Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med351: 2611–261815602021
10. Pussinen PJ,, Nyyssönen K,, Alfthan G,, Salonen R,, Laukkanen JA,, et al. (Year: 2005) Serum antibody levels to Actinobacillus actinomycetemcomitans predict the risk for coronary heart disease. Arterioscler Thromb Vasc Biol25: 833–83815692101
11. Wang Z,, Klipfell E,, Bennett BJ,, Koeth R,, Levison BS,, et al. (Year: 2011) Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature472: 57–6321475195
12. Wiedermann CJ,, Kiechl S,, Dunzendorfer S,, Schratzberger P,, Egger G,, et al. (Year: 1999) Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol34: 1975–198110588212
13. Amar J,, Ruidavets JB,, Bal Dit Sollier C,, Bongard V,, Boccalon H,, et al. (Year: 2003) Soluble CD14 and aortic stiffness in a population-based study. J Hypertens21: 1869–187714508193
14. Vlachopoulos C,, Dima I,, Aznaouridis K,, Vasiliadou C,, Ioakeimidis N,, et al. (Year: 2005) Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation112: 2193–220016186422
15. Koren O,, Spor A,, Felin J,, Fåk F,, Stombaugh J,, et al. (Year: 2011) Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A108 Suppl 1: 4592–459820937873
16. Amar J,, Serino M,, Lange C,, Chabo C,, Iacovoni J,, et al. (Year: 2011) D.E.S.I.R. Study Group. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia54: 3055–306121976140
17. Kriegel MA,, Sefik E,, Hill JA,, Wu HJ,, Benoist C,, et al. (Year: 2011) Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc Natl Acad Sci U S A108: 11548–1155321709219
18. Greenblum S,, Turnbaugh PJ,, Borenstein E, (Year: 2012) Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci U S A109: 594–59922184244
19. Walker AW,, Sanderson JD,, Churcher C,, Parkes GC,, Hudspith BN,, et al. (Year: 2011) High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol11: 721219646
20. De Palma G,, Nadal I,, Medina M,, Donat E,, Ribes-Koninckx C,, et al. (Year: 2010) Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol10: 6320181275
21. Fumeron F,, Aubert R,, Siddiq A,, Betoulle D,, Péan F,, et al. (Year: 2004) Epidemiologic Data on the Insulin Resistance Syndrome (DESIR) Study Group. Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study. Epidemiologic Data on the Insulin Resistance Syndrome (DESIR) Study Group. Diabetes53: 1150–115715047634
22. Coenye T,, Vandamme P, (Year: 2003) Intragenomic heterogeneity between multiple 16S ribosomal RNA operons in sequenced bacterial genomes. FEMS Microbiol Lett228: 45–4914612235
23. Rigat B,, Hubert C,, Alhenc-Gelas F,, Cambien F,, Corvol P,, et al. (Year: 1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest86: 1343–13461976655
24. Marcadet A, O'Connell P, Cohen D (1987) Standardized Southern blot workshop technique. In: Dupont B (ed) Histocompatibilty testing, vol 1. Springer, New York, pp 553–60
25. Valladares R,, Sankar D,, Li N,, Williams E,, Lai KK,, et al. (Year: 2010) Lactobacillus johnsonii N6.2 Mitigates the Development of Type 1 Diabetes in BB-DP Rats. Plos one5: e1050720463897
26. Desvarieux M,, Demmer RT,, Rundek T,, Boden-Albala B,, Jacobs DR Jr,, et al. (Year: 2005) Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation111: 576–58215699278
27. Zhu J,, Nieto FJ,, Horne BD,, Anderson JL,, Muhlestein JB,, et al. (Year: 2001) Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation103: 45–5111136684
28. Haraszthy VI,, Zambon JJ,, Trevisan M,, Zeid M,, Genco RJ, (Year: 2000) Identification of periodontal pathogens in atheromatous plaques. J Periodontol71: 1554–156011063387
29. Ott SJ,, El Mokhtari NE,, Musfeldt M,, Hellmig S,, Freitag S,, et al. (Year: 2006) Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation113: 929–93716490835
30. Katz JT,, Shannon RP, (Year: 2006) Bacteria and coronary atheroma: more fingerprints but no smoking gun. Circulation113: 920–92216490832
31. Turnbaugh PJ,, Hamady M,, Yatsunenko T,, Cantarel BL,, Duncan A,, et al. (Year: 2009) A core gut microbiome in obese and lean twins. Nature457: 480–48419043404
32. Turnbaugh PJ,, Ley RE,, Mahowald MA,, Magrini V,, Mardis ER,, et al. (Year: 2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature444: 1027–103117183312
33. Garrett WS,, Gordon JI,, Glimcher LH, (Year: 2010) Homeostasis and inflammation in the intestine. Cell140: 859–87020303876
34. Kinloch AJ,, Alzabin S,, Brintnell W,, Wilson E,, Barra L,, et al. (Year: 2011) Immunization with Porphyromonas gingivalis enolase induces autoimmunity to mammalian α-enolase and arthritis in DR4-IE-transgenic mice. Arthritis Rheum63: 3818–382321953289
35. Lundberg K,, Wegner N,, Yucel-Lindberg T,, Venables PJ, (Year: 2010) Periodontitis in RA-the citrullinated enolase connection. Nat Rev Rheumatol6: 727–73020820197
36. Henao-Mejia J,, Elinav E,, Jin C,, Hao L,, Mehal WZ,, et al. (Year: 2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature482: 179–18522297845
37. Ogilvie LA,, Jones BV, (Year: 2012) Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease?Gut61: 1642–322490526
38. Andraws R,, Berger JS,, Brown DL, (Year: 2005) Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA293: 2641–264715928286
39. De La Cochetière MF,, Durand T,, Lepage P,, Bourreille A,, Galmiche JP,, et al. (Year: 2005) J Clin Microbiol43: 5588–559216272491
40. Dethlefsen L,, Huse S,, Sogin ML,, Relman DA, (Year: 2008) The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol6: e28019018661
41. Dethlefsen L,, Relman DA, (Year: 2011) Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A108 Suppl 1: 4554–456120847294
42. Erridge C,, Attina T,, Spickett CM,, Webb DJ, (Year: 2007) A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr86: 1286–9217991637
43. Hasday JD,, Bascom R,, Costa JJ,, Fitzgerald T,, Dubin W, (Year: 1999) Bacterial endotoxin is an active component of cigarette smoke. Chest115: 829–83510084499
44. Bonora E,, Targher G, (Year: 2012) Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol9: 372–8122565095


[Figure ID: pone-0054461-g001]
doi: 10.1371/journal.pone.0054461.g001.
Figure 1  Proteobacteria phylum within blood microbiota.

Box and wisker plot, showing medians (dot in middle of box, quartiles at end of box, and as wiskers the extremes), of Eucbacteria: 16S ribosomal DNA gene sequences common to the vast majority of bacteria phyla (Eubac) according to Pbac: 16S ribosomal DNA sequences that belong to the Proteobacteria phylum (both variables are log transformed).

[Figure ID: pone-0054461-g002]
doi: 10.1371/journal.pone.0054461.g002.
Figure 2  Adjusted Hazard ratio of having primary cardiovascular outcome by tertiles of Eubacteria (Eubac) and Proteobacteria (Pbac).

[TableWrap ID: pone-0054461-t001] doi: 10.1371/journal.pone.0054461.t001.
Table 1  Characteristics of the D.E.S.I.R. study population, mean ± SD, geometric */÷ eSD or n(%), according to presence of incident cardiovascular events during the 9 year follow-up.
Free of cardiovascular events (n = 3863) With cardiovascular events (n = 73) P
Men (n (%)) 1895 (49) 65 (89) <0.0001
Age (years) 47±10 55±8 <.0001
Body mass index (kg/m2) 24.6±3.7 26.8±3.7 <.0001
Waist perimeter (cm) 83±11 93±12 <.0001
Systolic blood pressure (mm Hg) 131±15 144±17 <.0001
Diastolic blood pressure (mm Hg) 80±9 86±10 <.0001
Total cholesterol (mmol/l) 5.71±0.97 6.21±1.07 <.0001
HDL-cholesterol (mmol/l) 1.64±0.43 1.38±0.37 <0.0001
LDL-cholesterol (mmol/l) 3.58±0.90 4.13±0.91 <.0001
Triglycerides (mmol/l) * 0.97*/÷1.67 1.35*/÷1.65 <.0001
Fasting blood glucose (mmol/l) 5.34±0.77 6.13±1.98 <.0001
Fibrinogen (g/l) 2.99±0.65 3.15±0.60 0.04
Leukocytes (109/l) 6.36±1.71 7.14±1.95 0.0001
Aspartate aminotransferase (UI/l) 20.50±9.87 24.12±12.04 0.002
Alanine aminotransferase (UI/l) 25.63±16.88 32.75±21.07 0.0004
Eubac gene (ng/µl) *, , * 0.07*/÷2.86 0.05*/÷3.06 0.02
Pbac gene (ng/µl) *, §, * 0.20*/÷4.34 0.22*/÷5.18 0.7
Current smokers (n (%)) 984 (25) 27 (37) 0.03
Hypertension (n (%)) 1391 (36) 52 (71) <0.0001
Diabetes (n (%)) 84 (2) 13 (18) <0.0001

*Log transformed for analysis.

Eubac denotes 16S ribosomal DNA gene sequences, common to the vast majority of the bacteria phyla.

§Pbac denotes 16S ribosomal DNA gene sequences that belongs to the Proteobacteria phylum.

[TableWrap ID: pone-0054461-t002] doi: 10.1371/journal.pone.0054461.t002.
Table 2  Major cardiovascular risk factors by tertiles of Eubacteria (Eubac).
Tertiles of Eubac
≤0.039 ng/µL 0.040 to 0.093 ng/µL >0.093 ng/µL P trend
n = 1299 n = 1338 n = 1299
Men (n (%)) 638 (49) 652 (49) 670 (52) 0.1
Age (years) 46±10 47±10 48±10 0.0002
Body mass index (kg/m2) 24.7±3.7 24.6±3.7 24.6±3.5 0.5
Waist perimeter (cm) 83±12 83±12 83±11 0.6
Systolic blood pressure (mm Hg) 131±15 130±15 132±16 0.06
Diastolic blood pressure (mm Hg) 80±9 79±9 81±10 0.008
Total cholesterol (mmol/l) 5.74±0.98 5.73±0.97 5.71±0.97 0.3
HDL-cholesterol (mmol/l) 1.62±0.43 1.66±0.43 1.61±0.42 0.01
LDL-cholesterol (mmol/l) 3.60±0.91 3.58±0.90 3.58±0.90 0.3
Fasting blood glucose (mmol/l) 5.39±0.82 5.34±0.69 5.34±0.91 0.03
Fibrinogen (g/l) 2.93±0.58 2.95±0.60 3.12±0.74 0.0001
Aspartate aminotransferase (UI/l) 20.65±9.44 20.65±9.55 20.39±10.74 0.74
Alanine aminotransferase (UI/l) 25.19±15.55 25.43±17.56 26.67±17.74 0.06
Current smokers (n (%)) 382 (29) 321 (24) 308 (24) 0.0004
Diabetes (n (%)) 30 (2) 29 (2) 38 (3) 0.2

[TableWrap ID: pone-0054461-t003] doi: 10.1371/journal.pone.0054461.t003.
Table 3  Major cardiovascular risk factors by tertiles of Proteobacteria (Pbac).
Tertiles of Pbac
≤0.095 ng/µL >0.095 to <0.33 ≥0.33 ng/µL P trend
n = 1299 n = 1338 n = 1299
Men (n (%)) 640 (49) 648 (48) 672 (52) 0.1
Age (years) 47±10 47±10 48±10 0.01
Body mass index (kg/m2) 24.8±3.8 24.5±3.6 24.7±3.7 0.3
Waist perimeter (cm) 83±12 83±11 84±12 0.8
Systolic blood pressure (mm Hg) 131±15 130±15 132±16 0.01
Diastolic blood pressure (mm Hg) 80±9 79±9 81±10 0.002
Total cholesterol (mmol/l) 5.74±0.98 5.73±0.97 5.71±0.97 0.4
HDL-cholesterol (mmol/l) 1.63±0.43 1.64±0.42 1.62±0.43 0.4
LDL-cholesterol (mmol/l) 3.60±0.91 3.58±0.90 3.58±0.90 0.5
Fasting blood glucose (mmol/l) 5.39±0.82 5.34±0.69 5.34±0.91 0.2
Fibrinogen (g/l) 2.93±0.58 2.95±0.60 3.12±0.74 0.0001
Aspartate aminotransferase (UI/l) 20.80±9.72 20.00±8.60 20.90±11.29 0.04
Alanine aminotransferase (UI/l) 25.55±15.85 24.22±14.60 27.56±19.96 <.0001
Current smokers (n (%)) 362 (28) 353 (26) 296 (23) 0.001
Diabetes (n (%)) 30 (2) 26 (2) 41 (3) 0.08

[TableWrap ID: pone-0054461-t004] doi: 10.1371/journal.pone.0054461.t004.
Table 4  Standardized hazards ratios for an incident cardiovascular outcome.
Hazard ratio(95% CI) P value
Model 1
Eubac 0.68 (0.53–0.88) 0.004
Model 2
Eubac 0.50 (0.35–0.70) <0.0001
Pbac 1.56 (1.12–2.15) 0.007

Models 1 and 2 were adjusted for gender, smoking status, LDL-cholesterol, fibrinogen, hypertension and diabetes. In addition , in model 2 Pbac was included.

Article Categories:
  • Research Article
Article Categories:
  • Medicine
    • Cardiovascular
      • Acute Cardiovascular Problems
      • Myocardial Infarction
    • Clinical Research Design
      • Cohort Studies
      • Longitudinal Studies
    • Epidemiology
      • Biomarker Epidemiology
      • Cardiovascular Disease Epidemiology
    • Neurology
      • Cerebrovascular Diseases
        • Ischemic Stroke

Previous Document:  Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma.
Next Document:  Efficacy of intensive control of glucose in stroke prevention: a meta-analysis of data from 59197 pa...